Can we intercept PsA?

      Retro study 394 PSO pts 17 yrs follow-up 86 PsA

      TNFi linked to higher PsA incidence vs IL- MoA
      T

      Aurelie Najm AurelieRheumo

      1 week 1 day ago
      Can we intercept PsA? Retro study 394 PSO pts 17 yrs follow-up 86 PsA TNFi linked to higher PsA incidence vs IL- MoA TNFi 45% vs IL-17i 14% vs IL-23i 10% vs IL-12/23i 11% After adjustment IL-17i HR 0.35 IL-23i HR 0.17 Needs prospective confirmation! #OP072 #EULAR2026 https://t.co/88RaukjLjY
      22% of psoriasis patients developed #PsAover 17 years of follow-up. PsA occurred in 44% of TNFi-treated vs only 9–14%

      Antoni Chan MD (Prof) synovialjoints

      1 week 1 day ago
      22% of psoriasis patients developed #PsAover 17 years of follow-up. PsA occurred in 44% of TNFi-treated vs only 9–14% of those on IL-23i or IL-12/23i. Time to discuss "preventive biologics" in PsO? Prospective controlled trials are needed Abstr#072 @RheumNow #EULAR2026
      In a 17-year real-world psoriasis cohort, patients on IL-17i had 75% lower odds and IL-23i patients had 84% lower odds o

      Antoni Chan MD (Prof) synovialjoints

      1 week 1 day ago
      In a 17-year real-world psoriasis cohort, patients on IL-17i had 75% lower odds and IL-23i patients had 84% lower odds of developing #PsA vs TNF inhibitors. Is biologic class selection a PsA interception strategy? Prospective controlled trials are needed Abstr#072 @RheumNow https://t.co/jpdZjGK7VV
      Small interventional synovial biopsy precision medicine study

      CD117 high pts n=15 = better response to IL17i or IL23i i

      Aurelie Najm AurelieRheumo

      1 week 1 day ago
      Small interventional synovial biopsy precision medicine study CD117 high pts n=15 = better response to IL17i or IL23i inhibition vs. TNFi w/ -DAPSA -13.5, -12.8 vs. -7.5 respectively Higher BL levels of tissue inflammation in Responders vs. NR More robust study design needed https://t.co/7jNff6lUJ6
      #OP085 from Sweden adds more real-world data to the JAKi safety discussion at #EULAR2026. In >26000 RA treatment init

      Mrinalini Dey DrMiniDey

      1 week 1 day ago
      #OP085 from Sweden adds more real-world data to the JAKi safety discussion at #EULAR2026. In >26000 RA treatment initiations, JAKis were associated with higher VTE risk vs TNFi (HR 1.89), with similar findings persisting in 2021-2024 data. @RheumNow https://t.co/YRjPNZ8mmo
      💉 Add tirzepatide to biologics in obese #PsA?

      #POS0050: Yes! Propensity score-matched study (n=93):
      better PROs, HA

      Nelly ZIADE 🍀 Nellziade

      1 week 1 day ago
      💉 Add tirzepatide to biologics in obese #PsA? #POS0050: Yes! Propensity score-matched study (n=93): better PROs, HAQ & PASI at 6 months #EULAR2026 @RheumNow @vincevenerito https://t.co/rrhNKZByjc

      Catch up on Conference Podcasts

      ×